Market closed
Nuvation Bio/$NUVB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Ticker
$NUVB
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
203
Website
Nuvation Bio Metrics
BasicAdvanced
$905M
Market cap
-
P/E ratio
-$2.23
EPS
1.36
Beta
-
Dividend rate
Price and volume
Market cap
$905M
Beta
1.36
52-week high
$4.16
52-week low
$1.40
Average daily volume
2.6M
Financial strength
Current ratio
9.57
Quick ratio
9.374
Long term debt to equity
0.196
Total debt to equity
2.226
Interest coverage (TTM)
-533.52%
Management effectiveness
Return on assets (TTM)
-13.98%
Return on equity (TTM)
-95.54%
Valuation
Price to revenue (TTM)
297.599
Price to book
1.8
Price to tangible book (TTM)
1.81
Price to free cash flow (TTM)
-6.477
Growth
Earnings per share change (TTM)
487.59%
3-year earnings per share growth (CAGR)
73.59%
What the Analysts think about Nuvation Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Nuvation Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Nuvation Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $905M as of December 21, 2024.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of December 21, 2024.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.